TLR9 and neoplasm: Additionally, combination therapies involving TLR7 and TLR9 agonists with PD-1 blockades have increased the proportion of M1 to M2 tumor-associated macrophages and induced infiltration of tumor-specific IFN-γ-producing CD8+ T cells to elicit tumor-specific adaptive immune responses and hence tumor suppression (102).